Takeda Pharmaceutical (Takeda) and Pfizer have entered into an agreement under which Pfizer in China will co-promote Takeda’s Actos (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in the country.
The co-promotion agreement is expected to build on the current sales capability for Actos in China, by increasing the number of medical representatives supporting the sales and marketing of the product and expanding the product reach utilising the territory coverage of Pfizer. Pfizer’s Chinese affiliate will receive a fixed ratio of Actos net sales.
Reportedly, Actos, for the treatment of type 2 diabetes, has been sold in China since 2004 by Tianjin Takeda Pharmaceuticals, a joint venture of Takeda and Tianjin Lisheng Pharmaceutical.
Alan MacKenzie, executive vice president of international operations at Takeda Pharmaceuticals, said: “Takeda has a significant opportunity to increase our presence in China, and we are pleased to be partnering with Pfizer to make Actos even more widely available to patients in China.”